Adaptive Biotech Reports Strong Q1 Revenue Growth Driven by clonoSEQ Performance
Adaptive Biotechnologies (NASDAQ:ADPT) reported a 35% year-over-year revenue increase to $70.9 million in Q1 2026, driven primarily by its Minimal Residual Disease/MRD business and the performance of its flagship clonoSEQ product.
Tickers: $ADPT